Steve. focusing Thank on my Today, be comments current you, business and the franchises. I'll DAYBUE NUPLAZID state our of in
caregivers results messaging business DAYBUE, we X care elements and experiences with my Starting health that the XXXX, and long-term core new comments and real-world based of will key revenues. value First, areas: data address date the to from the providers are drive in on
to Slide turn X. Please
XXXX. how business Let's progressed start has the far with thus in
to in patients active DAYBUE. growth total quarter on second return The a marked
surge new know, slowdown dynamic, during the new patient increase a in soon you saw first after associated first in a the starts. in quarter the the resulted quarter first As with discontinuations active That in coupled large launch, starts decline quarter. with in patients numerical total
by in patients was driven demand sequential a total recovery numerical quarter in second active and Our in a decrease increase discontinuations.
First, a second first starts weekly on we new of quarter. XX% patient in the an with significantly coming in increase quarter generated discontinuations, time, first in higher DAYBUE in lower At quarter. versus the new than XX% starts the we experienced rate decreasing same weekly the
the than of line new total with in decreasing our therapy growing active projected. than therapy made both of patients we This starts, rate expectations fronts lower rate patients numerical been is While our but on anticipated. progress in quarter, patient function of second was on important slower while our on a increasing discontinuations has
clinical to on our high-volume we the of each and As need and patients. expand so substantially can practices, educate whom obviously caregivers community penetration we their positions to are benefits DAYBUE best they more benefits those in institutions there we're communicate engaging, of
Our and increased just indicates this treatment the in will takes this audience. over it to penetration time past broader reach these settings quarter happen
now the the business turn the of and starts. of view to me patient our for to second opportunities let that, half accelerate new year With
initiated population DAYBUE available, is is grow XXX of DAYBUE X, continued the course, the the patients After of back early of United treatment. in we've XX still where patients active all of second were approximately XX% the By and on our As we in which less late we the quarter. Rett August XXXX. of States third to the XX% fully close than means Rett market, had in on diagnosed have This, penetration months quarter, to therapy,
volume. Today, of Rett patients treated. all greater institutions both X/X coming remaining as all DAYBUE in penetration of prescriptions high-volume well to COE the continuing COEs X/X of from the where almost are we approximately in with segments centers a X/X as stream like driven of excellence, these where steady are the have sourced also we see in be Beyond community practices, X
caregiver community. communicating year, with points can last experience. care own significant are establishment this launched point health are back community body clinical described, these further to into providers real-world as we of how the the high source further potential can where As their body DAYBUE these time of continue real-world We're provide of business how in inform contribute over of to understanding the their DAYBUE experiences and communities have the now our of the previously a in greater experiences this practices. Having the at data practices. We benefits these and context in proof now both penetration from mid-April we relevant achieve and in to of volume we expect a shift we best underscore LAVENDER consistent of results
LOTUS, families, further. XX studies: management benefits IRS LILAC-X over diversity in essential It's or that as into durability we Liz Slide we treatment the of GI they the utilization to detail F expect June conference X with and time. this Let's posters and of end, her can number, over caregivers at turn to to to describing in their that LILAC-X, will go section. to presented DAYBUE more speak physicians recently well discuss as where of benefits To time. experience the communicate and strategies. both seen
success experiencing a the very benefiting the show patient well we've are But us our and more Those clinical patient world as paint seen quarter, results that understandable all severities, loved terms studies. picture we're seeing told in the with of ones from expressed more to by can caregivers what ages treatment in intended stories are As are real now sharing importantly, we range the families whose stories caregivers. disease wide DAYBUE. DAYBUE as in enter third be are to consistent for the we across relevant
evidence of in seeing manageable the body what that the LAVENDER are real growing diarrhea On a management front, the more be in was may observed world GI than we study.
was III GI plan, benefits are study. and examples Today, are authentic associated Phase protocol tolerability. there management with equipped a management reminder, patients coupled to HCPs GI teams and commercial benefits caregivers our with with and medical real-world of the a DAYBUE's than ever better proactive educate the proactive As no about seeing,
long-term value Slide the I'll revenues. core Let's turn of DAYBUE business where drive to and topic, XX my third that elements our discuss
size I'll the to First, physician treat. intent opportunity start with and of the
a States. noted minutes ago, Rett diagnosed few the patients approximately X,XXX there a today, I As of is sizable United population in
continue with leaving a large expect grow the the have to We close to further therapy, X,XXX to X,XXX initiated estimated to approximately Of the to prevalent and the drug. today, population DAYBUE population. gap X,XXX this patients continue total grow XX% diagnosed very opportunity diagnosed
reason I'd XX further of of are like market of reported syndrome their HCPs months, a DAYBUE. DAYBUE. and informing life over increase elements extremely proactively recommend Rett the DAYBUE Rett the expect of site than our When XX% quality view prescriptions they aware expand caregiver extremely in are to their a Today, in XX% their request remaining to to honor are the research, to a XX% our Surveyed for share to more that next of to XX% DAYBUE of state fully few caregiver approximately of key of of aggregate treat HCPs primary physicians treating they attractiveness patients. opportunity. eligible as prescribing. willing willing to the Physician asked, DAYBUE improvement the
this remain III our of therapy patients patients that of durability months half patients with will for remains previously than XX% on XX% number population approximately reports, placebo X our DAYBUE program have initiate stated, a our Knowing therapy from in a therapy of that we've sizable observed having Real-world opportunity and the improvement initiate study. on additionally is reached rate X-month the enduring percentage XX real demonstrating today on our Phase XX point, and who as be with the informs in at than higher percentage real-world points DAYBUE. DAYBUE on enduring on world, Second, LILAC-X expectation much larger persistency more Consistent been patients persistency a point long-term years, our X who that now track we prior on DAYBUE about continuing now to rollover more today, we see specifically this patients. the trials, measure. or DAYBUE the clinical what
rates. to Third, DAYBUE utilization let's turn
we've many words, the and patient, choose best and the if the to patient dose label below dose they to the at dosing may described, of some start therapeutic In not physicians decrease In choose may they work As label to determine their for full label upon may cases is initiating titrate or DAYBUE, their that up, start there other both up they dose. XXX% dose. previously down. and dose the
our described Following or patients across may, dose the which other initiation entire any data XX I between completeness, to the percentage that of is effectiveness access these the of and have patients are with to population believe them. further drivers label of consideration we And during take growing real-world we'll dose established the multiple average of titration and value patients rates of types time, includes indicates adjustments treatment clinical range. is we've patients take When leverage patient low over to time evidence DAYBUE as see consumption a paid XX% mature. relatable long-term mix, XX% the patient DAYBUE, period, sake consistently covering now approximately label. plans Fourth, greater of dose. having policies our this demonstrating written we our more XX% monthly post in at who DAYBUE patient HCPs dose treatment conversion into product therapy much of DAYBUE across our from We to to largely pause We titrating, than full to body rate and is that to caregivers. reasons, comorbidities as time continue finally, their cohorts for and in the above, due payer XX%
Slide Please an NUPLAZID. XX for on update turn to
profile quarter This our and Parkinson's Turning patients hallucinations well an the second update. as by has delusions as with label outstanding been evidence NUPLAZID's clinical leveraging for growth. performance to of studies suffering NUPLAZID. demonstrating from real-world year-over-year We XX% driven had unique year's last disease-related
and NUPLAZID of Our X over for choice educating job off-label to and demonstrate programming benefits efforts evidence need effectively these the the the real-world HCPs their sales opposed data the We've to important antipsychotics. first team peer-to-peer treatment the as of bolstered has published in PDP done about for atypical past excellent peers years, initiating educating differential PDP findings patients NUPLAZID of an which studies with consider these key experts with as on PDP. these best sets treating with
these label, that patient the address addressing can In the NUPLAZID's addition approved to important suffering without year, to patients these new help with confusion FDA Today, clearly about change NUPLAZID's prescribed questions their our population. for with decision a it clear dementia, existed psychosis Parkinson's disease NUPLAZID make be or addressable clinicians data sets, treat prescribers with making last sales can teams positive best that PDP. and thereby from patients to
broader Parkinson's slide. relative how XX. are X turn to takeaway this the There to disease points performing turn to NUPLAZID Slide at from market. now is look Let's Please
has hard that market First, upheaval Parkinson's Parkinson's in of care years of during Parkinson's who significant and observed the given and age reside patients number long-term the stabilized community now we've hit pandemic people the condition advanced was medical following the as the facilities. with particularly disease
of quarters been now, utilization of motor in a Parkinson's therapy several stable. has For carbidopa/levodopa the row staple
as new NUPLAZID's subsequent first the new other patient quarter in quarters. our NUPLAZID second us patient increasing up second new of and continuing progress declined quarter chart, the terrific during X% patients patient This second sequentially, antipsychotics the for is to the grew while in this the see can starts half XX% of you and leading for as nicely in share year importantly, More time starts starts X%, become new in period. sets starts
population of The second above share continuing NUPLAZID we a setting. as is as patient for described patient the quarter our among This ended both ever also performance community milestone quarter marked new of significant a number with well as new highest in starts. on strong gains the the I patients reflection
to turn Slide Please XX.
we growing hallucinations disease. of having caregivers patients, in exists competitors an gap that to share treated patients today With a Parkinson's stabilized further both role engage our attractive awareness to NUPLAZID's market central as delusions as and from gaining the and bridge these the PDP of see well now treating and non-motor NUPLAZID and regarding opportunity symptoms
the at research what look this market Let's that up backs and we do. to plan
decline can DTC patient from patients, raise is and you recently. in launch delusions see new unbranded awareness XX% more associated down peak chart to a XXXX slide, unaided May directly to As we in from address this and and soon X% Parkinson's disease on around intended the awareness identify of and will help of this caregiver significantly to speaking awareness by caregivers a hallucinations this To among with campaign of audience. targeted patients
is disease. treatment if indicates hallucinations NUPLAZID, XX% for request the of and NUPLAZID a delusions physicians educating patients As turnover. patients with most On we disease these research evidence approximately advance PDP associated market not type they these our know are they of forward and Despite intended suffering upon campaign. has caregiver for DTC a to we from identifying It's suffering on of awareness patient look awareness, patient they prescribe request. the this upcoming seen likely progress that therefore with current not and data. of messaging. of delusions, extremely level where whom audience out a patients not months. XX% campaigns. These treatment a dynamic has assess low we of together recently both loved of from as critical our sharing of families undoubtedly holidays is the be these PDP, reminder, of changes business fall potential by awareness only population to launched disease. patients their a treatment the and of new from to The top symptoms and will driven continue today low see they It's as function of with FDA-approved non-motor our programs in ones according We a of and prior the to option about NUPLAZID their a to been this awareness delusions get also awareness designed this as have a the branded high at and the of caregivers conditions, dynamics We know HCP to we've Parkinson's educational improving indicate strength NUPLAZID is the HCPs raise option benefited a with heard leading as discussions of it upcoming or that will as and roll in have label hallucinations Thus, to leads sales campaign studies shared X well us in to success many fewer NUPLAZID That that need. that complement this receiving of for levels our our hallucinations the among approximately as year. some receiving both real-world NUPLAZID low market positive this resulted now clarification. latest with guidance or increase
are guidance and we details provide clear, is for campaigns impact relying the shortly. XXXX campaigns To Mark of absorb establish increasing will be new projected to our we beyond. on as realized able Equally revised not be XXXX. these importantly, in be the our expected our investments without SG&A in to guidance. XXXX will campaigns the new DTC to these
and Head I'll Liz studies Development, Research programs, to update pipeline an on provide starting our Thompson, of it clinical Vice XX. turn on President, now Slide Executive and over to
